Author:
Liu Deqin,Luo Renyin,Zhou Qian,Li Mei
Reference54 articles.
1. Ghafouri-Fard S, Honarmand Tamizkar K, Hussen BM, Taheri M. MicroRNA signature in liver cancer. Pathol Res Pract. 2021;219:153369.
2. Heinrich S, Craig AJ, Ma L, Heinrich B, Greten TF, Wang XW. Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. J Hepatol. 2021;74:700-15.
3. Cheng CS, Tan HY, Zhang C, Chan YT, Zhang ZJ, Man K, Yuen MF, Wang N, Feng Y. Berberine suppresses metastasis and recurrence of hepatocellular carcinoma by targeting circulating tumour cells: Abridged secondary publication. Hong Kong Med J. 2022;28(6 Suppl):10-1.
4. Cassese G, Han HS, Cho JY, Lee HW, Lee B, Troisi RI. Selecting the best approach for the treatment of multiple non-metastatic hepatocellular carcinoma. Cancers. 2022;14(23):5997.
5. Chen Z, Shen Z, Wang X, Wang P, Zhu X, Fan J, Li B, Xu W, Xiao J. Combination of bone-modifying agents with immunotarget therapy for hepatocellular carcinoma with bone metastases. J Clin Med. 2022;11(23):6901.